Apotex has agreed to pay a $24.1m fine and has entered into a deferred prosecution agreement with the US Department of Justice to resolve price-fixing claims over the pravastatin cholesterol-lowering treatment, in the latest development arising out of ongoing generic pricing investigations in the US.
Apotex Pays Out Over US Price-Fixing Claims
Deal Over Pravastatin Includes $24.1m Fine And Deferred Prosecution Agreement
Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.
More from Legal & IP
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
In a precedential decision, the US Court of Appeals for the Federal Circuit has determined the meaning of the language “the patent” as it applies to patent-term extensions for reissued patents, in the context of Aurobindo’s bid to wipe out a reissued patent shielding Merck & Co’s Bridion (sugammadex) injectable.
• By
Novartis’ multi-front legal battle against MSN Laboratories over its Entresto blockbuster in the US has taken yet another twist, with a federal district court in New Jersey finding that a preliminary injunction was warranted against MSN’s product on the basis of infringement of Novartis’ trade dress.
• By
Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.
More from Generics Bulletin
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
Generics Bulletin previews the most noteworthy and anticipated events for April 2025.